Pharmaceutical Executive September 2014

September 2014 | Volume 0, Issue 0
From the Editor
Pharm Exec's latest Industry Audit sticks to the series' longtime standard of emphasizing transparent indicators of shareholder value.
Column
Pharma hopes for a deal are fading as the once-hot TTIP talks seem to be on the fizzle in Europe.
The legendary director's on-screen attitude to his TV show's sponsor, Bristol-Myers, caused some consternation—until the drugmaker saw the results.
Expansion of drug discount program ignites lawsuits, policy disputes.
The role of pharma medical affairs teams is taking on greater importance in the value chain.
Features
Defining the critical coaching steps necessary for top managers to realize their potential in an industry undergoing significant restructuring of human and financial capital.
After a dip into negative territory in 2012, 2013 delivered a resurgence in sales revenues, but the turnaround only spotlights a larger trend: the growing divide between the big Pharmas and the more nimble players.
Leaders from industry, government, and the CRO community examine Ireland's future as a magnet for life science investments, and what the nation must do to remain the leading exporter of finished pharmaceutical products.
Special Sponsored Section
By Pharmaceutical Executive Editors
Spain's recession-battered pharma sector adapts to a changing market environment and repositions itself for a return to healthy growth through expanding opportunities abroad.
native1_300x100
lorem ipsum